Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Piperacillin-tazobactam tolerability in patients with a labeled penicillin allergy (PIPPEN).

Antimicrobial stewardship & healthcare epidemiology : ASHE·2026
Same author

Gifts, Blind Spots, and Gray: Canadian Student Pharmacists' Perceptions of Pharmaceutical Industry Interactions.

American journal of pharmaceutical education·2026
Same author

Drug Coverage Policy and Legacy Prescribing: A Cross-Sectional Analysis in British Columbia.

Health science reports·2026
Same author

Sustainability pharmacy assistants in large urban hospital system.

The International journal of pharmacy practice·2026
Same author

Rising Escitalopram Use in British Columbia: Is it Rational and Evidence-Informed?

Canadian journal of psychiatry. Revue canadienne de psychiatrie·2025
Same author

Pharmacotherapy for hypertension in adults 60 years or older.

The Cochrane database of systematic reviews·2025

Related Experiment Video

Updated: Jun 10, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Hydralazine for essential hypertension.

Michael R Kandler1, Greg T Mah, Aaron M Tejani

  • 1Surrey Memorial Hospital Pharmacy, Fraser Health Authority, 13750 96 Avenue, Surrey, BC, Canada, V3V 1Z2.

The Cochrane Database of Systematic Reviews
|August 6, 2010
PubMed
Summary

No randomized controlled trials (RCTs) were found comparing hydralazine to placebo. Therefore, the effectiveness of hydralazine for hypertension treatment on mortality and morbidity remains uncertain.

More Related Videos

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
05:57

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

Related Experiment Videos

Last Updated: Jun 10, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
05:57

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Hypertension significantly increases the risk of stroke, myocardial infarction, and heart failure.
  • Hydralazine, a direct-acting vasodilator, has been used since the 1950s but is often superseded by newer agents due to tolerability.
  • Its low cost makes hydralazine a common choice in developing countries.

Purpose of the Study:

  • To evaluate the efficacy of hydralazine versus placebo in randomized controlled trials (RCTs).
  • To assess hydralazine's impact on mortality, cardiovascular events, adverse events, and blood pressure in primary hypertension.

Main Methods:

  • Searched major databases (Cochrane, MEDLINE, IPA, EMBASE) up to June 2009.
  • Included RCTs of oral hydralazine versus oral placebo for primary hypertension.
  • Excluded studies on secondary or gestational hypertension.

Main Results:

  • No RCTs comparing hydralazine to placebo were identified for this review.
  • Insufficient evidence exists to determine hydralazine's effects on mortality, morbidity, or blood pressure compared to placebo.
  • Reported adverse effects include reflex tachycardia, hemolytic anemia, vasculitis, glomerulonephritis, and lupus-like syndrome.

Conclusions:

  • Hydralazine may lower blood pressure, but this is based on non-RCT data.
  • The clinical outcome effects of hydralazine remain uncertain due to a lack of high-quality RCT evidence.